O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-10.39%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.91B
AUM Growth
+$5.91B
(-15%)
Cap. Flow
-$46.9M
Cap. Flow
% of AUM
-0.79%
Top 10 Holdings %
Top 10 Hldgs %
34.46%
Holding
169
New
32
Increased
33
Reduced
28
Closed
26
Top Buys
| 1 |
Arcutis Biotherapeutics
ARQT
|
$139M |
| 2 |
Biogen
BIIB
|
$132M |
| 3 |
Passage Bio
PASG
|
$110M |
| 4 |
Pfizer
PFE
|
$98.3M |
| 5 |
Gilead Sciences
GILD
|
$85.6M |
Top Sells
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$372M |
| 2 |
ARQL
Arqule Inc
ARQL
|
$99.8M |
| 3 |
Danaher
DHR
|
$98.1M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$93.8M |
| 5 |
Tandem Diabetes Care
TNDM
|
$68M |
Sector Composition
| 1 | Healthcare | 97.58% |
| 2 | Financials | 1.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
AtriCure
ATRC
$1.84B
| $31.2M | 0.52% | 928,189 +759,568 | +450% | +$25.5M |
|
52
Prothena Corp
PRTA
$441M
| $31.1M | 0.52% | 2,902,239 | – | – |
|
|
ATNX
53
DELISTED
Athenex, Inc. Common Stock
ATNX
| $31M | 0.52% | 4,009,346 +1,237,125 | +45% | +$9.58M |
|
54
Crinetics Pharmaceuticals
CRNX
$2.92B
| $30M | 0.5% | 2,039,282 | – | – |
|
|
NSTG
55
DELISTED
NanoString Technologies, Inc.
NSTG
| $28.7M | 0.48% | +1,192,400 | New | +$28.7M |
|
|
HARP
56
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $28.3M | 0.48% | 2,446,409 | – | – |
|
57
Acadia Healthcare
ACHC
$2.12B
| $25.3M | 0.43% | +1,380,160 | New | +$25.3M |
|
58
scPharmaceuticals
SCPH
$295M
| $25.2M | 0.42% | 3,409,865 | – | – |
|
59
TELA Bio
TELA
$70.5M
| $23.7M | 0.4% | 3,027,542 | – | – |
|
60
CRISPR Therapeutics
CRSP
$4.71B
| $23.4M | 0.39% | 551,200 -215,178 | -28% | -$9.13M |
|
|
XLRN
61
DELISTED
Acceleron Pharma Inc.
XLRN
| $23.1M | 0.39% | 257,549 +150,049 | +140% | +$13.5M |
|
|
BFYT
62
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $21.6M | 0.36% | +962,900 | New | +$21.6M |
|
63
Amgen
AMGN
$155B
| $21.3M | 0.36% | 105,200 -16,900 | -14% | -$3.43M |
|
64
Inspire Medical Systems
INSP
$2.77B
| $20.9M | 0.35% | 347,000 -1,000,000 | -74% | -$60.3M |
|
65
Zymeworks
ZYME
$1.12B
| $20.7M | 0.35% | +582,302 | New | +$20.7M |
|
66
Novo Nordisk
NVO
$251B
| $19.9M | 0.33% | 330,000 | – | – |
|
67
Aurinia Pharmaceuticals
AUPH
$1.58B
| $19.4M | 0.33% | 1,336,547 -1,008,900 | -43% | -$14.6M |
|
68
IQVIA
IQV
$32.4B
| $18.9M | 0.32% | 175,000 | – | – |
|
69
Xenon Pharmaceuticals
XENE
$2.98B
| $18.9M | 0.32% | 1,662,812 +1,028,000 | +162% | +$11.7M |
|
70
Alcon
ALC
$39.5B
| $17.9M | 0.3% | 351,380 | – | – |
|
71
AbbVie
ABBV
$372B
| $17.4M | 0.29% | +229,000 | New | +$17.4M |
|
|
SVA
72
DELISTED
Sinovac Biotech, Ltd
SVA
| $17.2M | 0.29% | 2,839,500 | – | – |
|
73
SI-BONE Inc
SIBN
$719M
| $16.5M | 0.28% | +1,381,300 | New | +$16.5M |
|
74
BiomX
PHGE
$14.3M
| $16.2M | 0.27% | 2,313,489 | – | – |
|
75
Verrica Pharmaceuticals
VRCA
$52.8M
| $16.2M | 0.27% | 1,479,733 | – | – |
|